Scantox acquires QPS’s Austrian neuropharmacology division (“QPS Neuro”).
QPS Neuro is a leading drug discovery Contract Research Organization (CRO) that specialises in neurodegenerative, rare diseases and mental disorders, including Alzheimer’s disease, Parkinson’s disease, ALS, dementia, autism and schizophrenia. QPS Neuro was founded in 1999 and employs more than 80 employees at the company’s state-of-the-art facility in Grambach, Austria.
Scantox was founded in 1977 and is the leading Nordic CRO, focused on pharmacology and regulatory toxicology. The company is headquartered in Denmark and its majority shareholder is Impilo, which is the leading Nordic healthcare investment company.
The acquisition of QPS Neuro will expand Scantox’s value chain coverage and reposition its existing drug discovery platform significantly.
QPS Neuro will continue its operations as part of the Scantox Group. The combined company now has more than 300 employees across six sites.
Accura acted as lead counsel to Scantox and Impilo in connection with the transaction.